Trial Profile
A Phase II Trial of Revlimid and 'On Demand' Dexamethasone Dosing in Patients With Newly Diagnosed Symptomatic Multiple Myeloma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Therapeutic Use
- 10 Dec 2019 Results assessing the peripheral blood immunophenotypes of newly diagnosed multiple myeloma patients received immunomodulatory imide drugs (lenalidomide) and corticosteroid (dexamethasone), released in 61st Annual Meeting and Exposition of the American Society of Hematology
- 28 Jun 2018 Status changed from active, no longer recruiting to completed.
- 28 Aug 2017 Planned End Date changed from 1 May 2017 to 1 May 2018.